Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis

Active, not recruiting

• Conditions: Acute Myocardial Infarction (AMI); Left Ventricular Remodeling; Major Adverse Cardiovascular Event; Plasma Multi-Omics

• Registration Number: NCT06885619
• Lead Sponsor: Beijing Anzhen Hospital

Brief Summary

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Detailed Description

Despite advances in AMI treatment, a substantial proportion of patients develop LVAR, leading to heart failure and increased MACE risk. Conventional biomarkers (e.g., troponin, NT-proBNP) lack sufficient predictive power for adverse outcomes. Multi-omics approaches - integrating proteomics(e.g., exosome proteomics), metabolomics, transcriptomics and lipidomics - offer a systems-level view that may uncover novel prognostic signatures.

Study Timeline

• Study Start: 2025-01-01
• Status Verified: 2025-02
• Study First Submitted: 2025-03-14
• Study First Submitted QC: 2025-03-14
• Study First Posted: 2025-03-20
• Last Update Submitted: 2025-07-29
• Last Update Posted: 2025-07-31
• Primary Completion: 2027-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Age ≥ 18 years.
2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
3. Willingness to provide informed consent.

Exclusion Criteria

1. Prior surgery or trauma.
2. Renal failure with glomerular filtration <30 ml/min.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
major adverse cardiovascular events	2025-1-1 to 2027-12-31	Identify T0 plasma multi-omics biomarkers that predict cardiac death, myocardial infarction, heart failure, and stroke.

Secondary Outcome Measures

Name	Time	Method
adverse cardiac remodeling	2025-1-1 to 2027-12-31	To assess the predictive ability of multi-omics biomarkers in T0 plasma for adverse cardiac remodeling, and to identify new candidate markers for forecasting this condition.

Trial Locations

Locations (1)

Beijing Anzhen Hospital, Capital Medical University.; 🇨🇳 Beijing, Beijing, China